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Abstract
Extrapulmonary effects of severe respiratory syncytial virus (RSV)
infection are not uncommon. Dr Eisenhut’s systematic review of
extrapulmonary manifestations of severe RSV infection clearly
demonstrates clinical consequences peripheral to the lung
parenchyma. The extrapulmonary impact of RSV infection raises
questions as to whether these are direct RSV effects (i.e., RSV
infection of site-specific tissue), secondary to parenchymal lung
disease and its causative respiratory failure, or the result of
inflammatory mediators dispersed from the provoked respiratory
epithelium.
“Oxygen is vitally important in bronchiolitis and there is
little evidence that any other treatment is useful.”
Reynolds and Cook (1963) [1]
Respiratory syncytial virus (RSV) was first identified in 1956
as the agent that causes chimpanzee coryza and
subsequently isolated from children in 1957. Since then this
medium-sized enveloped RNA paramyxovirus has been
recognised as the single most important virus causing acute
respiratory tract infections in children. The virus replicates in
nasopharyngeal epithelium and then spreads to lower
respiratory tract one to three days later. RSV infects
respiratory epithelial cells by attaching itself to the cell
surface by means of an envelope glycoprotein, the G
(attachment) protein. A second envelope glycoprotein, the F
(fusion) protein, mediates fusion with the epithelial cell
membrane along with adjacent cells, resulting in the
formation of multinucleated cells – syncytia – for which the
virus is named.
The vast majority of RSV research and studies have
concentrated on the lungs and the mechanics of pulmonary
immunopathology. Dr Eisenhut’s thorough systematic review
of extrapulmonary manifestations of severe RSV infection [2]
clearly demonstrates clinical consequences peripheral to the
lung parenchyma. It begs the question as to whether these
are direct RSV effects (i.e., RSV infection of that tissue) or
indirect, being secondary to parenchymal lung disease and
its causative respiratory compromise or consequential of
prowling inflammatory mediators?
RSV, like the other Paramyxiviridae, can infect non-epithelial
cells if it can gain access to the receptors on their surface, as
demonstrated by the use of monkey kidney cells for RSV
culture in vitro. The transit of RSV to distant organs would
have to be haematogenous. RSV-RNA has been detected by
RT-PCR in whole blood but not plasma of infants and
neonates [3,4], but this alone merely indicates cell-associated
RSV genome. This is not necessarily viable RSV and is likely
to be virus phagocytozed by neutrophils or monocytes. To
escape their white cell captors RSV would need to replicate
and break out, which has not yet been demonstrated. Viable
RSV floating freely in plasma would hold the potential for
distant RSV infection.
Evidence of deposition in distant organs comes from
detection in the myocardium [5,6], liver [7], and cerebrospinal
fluid [8]. However, strong convincing evidence of RSV-
related inflammation or infection of these sites is less
forthcoming. Elevated cardiac troponin levels in infants with
severe RSV infection are well described [9,10].
Unfortunately, this is not necessarily indicative of RSV-
directed myocardial injury, but more likely the result of (right)
heart strain secondary to severe lung parenchymal disease
[10]. Likewise, it is highly suggestive that raised hepatic
transaminases in this patient group are consequential to
hepatic congestion or ischaemia due to right heart failure,
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itself secondary to parenchymal lung disease and/or
pulmonary hypertension [11]. Proof of a RSV hepatitis would
take histological verification (i.e., liver biopsy), which for
ethical reasons is only ever going to occur postmortem.
Apnoeas and seizures undoubtedly occur in RSV infection,
but presently there is more support for RSV encephalopathy
than RSV encephalitis [12-15]. Unfortunately, many of the
reports fail to adequately adjust for the confounding
consequence that hypoxic episodes and hypercapnoea may
have on the patient’s neurological status. When not related to
hypoxic or electrolyte imbalance triggers, RSV’s central
influence/effect is probably related to released neurotoxic
inflammatory chemokines and cytokines [12,16,17]. Endo-
crine impact/consequences, although interesting, appear to
be the sequelae of severe RSV pulmonary disease and/or its
treatment. It is likely that occurrences of hyponatraemia and
hyponatraemic seizures are largely related to the use of
hypotonic/electrolyte-poor intravenous solutions [18]. Further
research is required to scrutinize whether the reported
neuroendocrine stress response in RSV bronchiolitis is no
more than an epiphenomenon reflecting severity of RSV
disease [19].
Most of the extrapulmonary effects are likely to be the end
result of released inflammatory mediators such as cytokines
and chemokines triggered by the RSV respiratory tract
infection. The antiviral and cell-mediated immune reaction to
RSV infection is primarily orchestrated by RSV-infected
respiratory epithelial cells and by alveolar macrophages. The
storm of T helper 1-type cytokines (IFNγ, IL-2, IL-12), T helper
2-type cytokines (IL-4, IL-5, IL-6, IL-10), antiviral interferons
(IFNα, IFNβ) and chemokines (C, CC, CXC and CX3C
subgroups) released from respiratory epithelial cells may
regulate the immune profile and reaction in outlying cells
[16,17,20]. Host genetic factors may further manipulate the
immune-augmented response at distant extrapulmonary sites.
Extrapulmonary effects of severe RSV infection are not
uncommon. Dr Eisenhut [2] is correct to remind clinicians of
them so that they may be vigilant to their occurrence and
consequences. The challenge for researchers is to discern
whether these extrapulmonary effects are as a result of site-
specific RSV infection or inflammatory mediators dispersed
from the provoked respiratory tract. Although the basic
sentiments of Reynolds and Cook [1] still ring true, the
understanding of RSV disease and its treatment options has
progressed over time.
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